Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease - Wallentin, Lars; Varenhorst, Christoph; James, Stefan; Erlinge, David; Braun, Oscar Ö; Jakubowski, Joseph A.; Sugidachi, Atsuhiro; Winters, Kenneth J.; Siegbahn, Agneta (European heart journal, 2008)
Keywords: Adult; Aged; Aspirin - therapeutic use; Cardiac and Cardiovascular Systems; Cardiology and Cardiovascular Disease; Clinical Medicine; Clopidogrel; Coronary artery disease; Coronary Artery Disease - drug therapy; Double-Blind Method; Female; Humans; Kardiologi; Kardiologi och kardiovaskulära sjukdomar; Klinisk medicin; Male; Medical and Health Sciences; MEDICIN; Medicin och hälsovetenskap; MEDICINE; Middle Aged; Piperazines - therapeutic use; Platelet Aggregation Inhibitors - therapeutic use; Platelets; Prasugrel; Prasugrel Hydrochloride; Thiophenes - therapeutic use; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use; Treatment Outcome; Trials; Prasugrel; Clopidogrel; Trials; Platelets; Coronary artery disease